Study wrapper · #476
Incretin-Based Therapies in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review of Emerging Cardiometabolic Disease Modification Beyond Glycemic Control.
Editor's note
This systematic review synthesises randomised evidence on semaglutide and tirzepatide in obesity-related heart failure with preserved ejection fraction, a phenotype the authors frame as distinctly inflammatory and metabolically driven. Across nine studies, including landmark trials and mechanistic substudies, incretin therapies were associated with improved heart-failure symptoms, exercise capacity, quality of life, inflammatory markers, and body weight, alongside favourable signals on cardiac remodelling and congestion physiology. Because this is a narrative-leaning systematic review without pooled effect sizes, and because it groups two agents, the results are best read as class-level and directional. The authors are careful to say that effects on remodelling reversal, arrhythmia, and cardiovascular mortality remain unproven. For semaglutide and tirzepatide readers, this is encouraging convergent context in obesity-related HFpEF, not endpoint-level proof.
Plain-language abstract
This review pulled together nine studies on using semaglutide and tirzepatide in people who have obesity-related heart failure where the heart still pumps fairly normally but does not relax well. Across the studies, these incretin medicines were linked to fewer heart-failure symptoms, better exercise ability, improved quality of life, lower inflammation markers, and weight loss, along with early signs of better heart structure and less fluid congestion. Because the review combined different studies and two different drugs without merging the numbers, the findings point in a promising direction rather than proving specific outcomes. The authors note that important questions, such as effects on irregular heartbeats and survival, are still unanswered and need longer trials.